Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pyrazolopyridinones as functionally selective GABAA ligands.

Wesley P Blackaby1, John R Atack, Frances Bromidge

  • 1Neuroscience Research Centre, Merck Sharp & Dohme Research Laboratories, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK. Wesley_Blackaby@Merck.com

Bioorganic & Medicinal Chemistry Letters
|September 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the psychosocial impact of prosthetic rehabilitation in patients with head and neck cancer: A scoping review.

The Journal of prosthetic dentistry·2026
Same author

Ovine forestomach matrix as a novel adjunct to promote healing of low output enterocutaneous fistulae in high-risk surgical patients.

Trauma case reports·2026
Same author

Model-Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC: A QSP Model for Alpelisib and Tipifarnib Combination.

Clinical pharmacology and therapeutics·2026
Same author

Accuracy of glomerular filtration rate estimation based on creatinine and cystatin C for monitoring moderate chronic kidney disease in adults: prospective, longitudinal cohort study.

BMJ (Clinical research ed.)·2026
Same author

Novel positive allosteric modulators of alpha 5 subunit-containing GABA<sub>A</sub> receptors (α5-GABA<sub>A</sub>Rs) reverse the hyperdopaminergic state in a neurodevelopmental model of schizophrenia.

Schizophrenia research·2026
Same author

End-of-life antibiotic stewardship: perspectives from the ESCMID Study Groups for antimicrobial stewardship and infections in the elderly.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026

Researchers optimized pyrazolopyridinones, which are ligands for the GABAA receptor benzodiazepine binding site. These compounds show selective targeting of the alpha3 subtype over the alpha1 subtype, crucial for developing new therapeutics.

Area of Science:

  • Medicinal Chemistry
  • Neuroscience
  • Pharmacology

Background:

  • GABAA receptor benzodiazepine binding site ligands are critical targets for neurological drug development.
  • Functional selectivity among GABAA receptor subtypes (e.g., alpha1 vs. alpha3) is key for therapeutic efficacy and minimizing side effects.
  • Pyrazolopyridinone scaffolds represent a promising chemical class for modulating GABAA receptor activity.

Purpose of the Study:

  • To explore structure-activity relationships (SAR) of 2,5-Dihydro-3H-pyrazolo[4,3-c]pyridin-3-ones.
  • To optimize compounds for enhanced functional selectivity towards the GABAA alpha3 receptor subtype over the alpha1 subtype.
  • To identify novel ligands with potential therapeutic applications targeting specific GABAA receptor subtypes.

Main Methods:

Related Experiment Videos

  • Systematic modification of the pyrazolopyridinone core structure.
  • Synthesis of novel chemical analogs.
  • In vitro assays to evaluate GABAA receptor binding affinity and functional selectivity (alpha3 vs. alpha1).

    • Main Results:

    • Detailed SAR studies revealed key structural features influencing subtype selectivity.
    • Several optimized compounds demonstrated significant functional selectivity for the alpha3 GABAA receptor subtype.
    • Identification of specific modifications that enhance affinity and selectivity profiles.

    Conclusions:

    • The pyrazolopyridinone scaffold can be effectively modified to achieve functional selectivity for GABAA alpha3 receptors.
    • These findings provide a foundation for developing subtype-selective GABAA modulators.
    • Optimized compounds hold potential as therapeutic agents for conditions modulated by GABAA alpha3 receptor activity.